Brookline Capital Acquisition Corp II (BCAC II) is a SPAC — a blank check company with no operations, no revenue, and no identified acquisition target. BCAC II raised $100M in its IPO by selling 10M units at $10.00 each, with proceeds held in trust until BCAC II completes a business combination with a private company or liquidates. BCAC II has 24 months from IPO close to complete a deal; if it fails, trust funds are returned to public shareholders and the sponsor's founder shares expire worthless. BCAC II's primary focus is healthcare and defense technology, though it can pursue targets in any industry. The sponsor, Brookline Capital Holdings II, is affiliated with Brookline Capital Markets, a boutique healthcare-focused investment bank. The sponsor acquired roughly 4.6M founder shares for $25,000 and also purchased $2.36M in placement units alongside the IPO. If a deal closes, those founder shares convert into Class A shares — creating enormous upside for the sponsor at minimal cost, while public shareholders bear the risk of a poor deal but retain the right to redeem at approximately $10.00 per share. BCAC II targets companies with enterprise values of $500M to $5B — well above the $100M in trust — meaning any deal will require significant additional financing, likely a PIPE or debt. BCAC II prefers established, profitable businesses or those with a clear path to profitability, and is particularly interested in special situations such as PE/VC-backed companies near capital-return deadlines, spinoffs, and family business successions.